Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Clinical effect of botulinum toxin type A combined with autologous fat grafting in patients with nasolabial fold depression

Wang RJ., Wang Y., Wu JF., Si TT.

Prospective Study with a reported sample of 30 on Skin Aging, Facial Rejuvenation, published in World J Clin Cases (2024) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
World J Clin Cases (2024)
Reported sample size
30
Source database
Europe PMC
PMID
39109017
PMCID
PMC11238783
DOI
10.12998/wjcc.v12.i22.4973
Citations
1

Abstract (original English)

Background Nasolabial fold (NLF) depression can affect the facial appearance of patients to some extent and increase their psychological burdens. In recent years, autologous fat grafting (AFG) combined with botulinum toxin A (BTX-A) injection (AFG + BTX-A injection) has been gradually applied in the treatment of patients with NLF depression. Although studies have been conducted on the efficacy and safety of AFG + BTX-A injection in treating NLF depression, the experimental design, observational indicators, and sample enrollment criteria vary remarkably, making it difficult to draw convincing and consistent conclusions. Thus, further relevant research is warranted. Aim To assess the esthetic improvement, efficacy, and safety of AFG + BTX-A injections in patients with NLF depression. Methods This study included 60 patients with NLF depression who were treated in our hospital from February 2019 to April 2021. These patients were categorized into control ( n = 30) and observation ( n = 30) groups. The observation group received AFG + BTX-A injection, whereas the control group underwent AFG only. All patients were evaluated using the wrinkle severity rating scale (WSRS) and global aesthetic improvement scale. The compactness of facial contours, skin evaluation indexes, adverse reactions, and satisfaction of the two groups were evaluated 3 months postoperatively. Results The WSRS sco

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research